The Pune-based Serum Institute of India has sought approval for the emergency use of the Oxford University vaccine. In its application to the Drugs Controller General of India (DCGI) the corporate has cited unmet medical needs thanks to the pandemic and within the interest of the general public at large.
SII is that the first Indian pharma to use for authorisation and it came after the US-based pharma Pfizer applied an emergency use authorisation for its Covid-19 vaccine within the country.
What are the plans for vaccine distribution?
In media reports, CEO Adar Poonawalla has maintained that India are going to be the most priority during the vaccine distribution. it'll then check out COVAX countries which are mostly in Africa. COVAX is that the World Health Organization-backed body that's purchasing shots for poor nations. the corporate also will specialise in bulk orders first before the vaccine becomes available for people .
While chatting with the media, Poonawalla said, "It’s vital we lookout of our country first, then continue to Covax then then other bilateral deals with countries. So I’ve kept it therein priority."
He had also said during a report by IANS, that full approval early next year will allow distribution on a 50-50 basis between the south Asian country and Covax.
Poonawalla had also said earlier that the Serum Institute is in talks with the govt for a sale agreement. He had said that the AstraZeneca vaccine will hit Indian markets by April 2021.
Recently Prime Minister Narendra Modi had also said during a n all-party meet early eight vaccines are at different stages of trial with their manufacturing assured in India and once the scientists provides a green signal it'll be released in a few weeks. He said that Central and government teams are working in tandem for the distribution of the vaccine against COVID-19, Modi said, adding that India has the expertise in vaccine distribution also as capacity. A special software Covin has also been developed for vaccine distribution which will help people track the status of the vaccine in India.